FDA Should CAP Its Superiority Trial Requirement For Antibiotics, Journal Says
Executive Summary
FDA should refrain from extending its moratorium on non-inferiority trials to antibiotics for the treatment of community-acquired pneumonia, an editorial in The Lancet Infectious Diseases advocates